Investment Analysts’ Recent Ratings Changes for Thermo Fisher Scientific (TMO)

Several brokerages have updated their recommendations and price targets on shares of Thermo Fisher Scientific (NYSE: TMO) in the last few weeks:

• 6/3/2026 – Thermo Fisher Scientific was downgraded by HSBC Holdings plc from “buy” to “hold”. They now have a $540.00 price target on the stock, down from $670.00.
• 6/3/2026 – Thermo Fisher Scientific was downgraded by HSBC Holdings plc from “buy” to “hold”. They now have a $540.00 price target on the stock, down from $670.00.
• 6/2/2026 – Thermo Fisher Scientific is now covered by Wolfe Research. They set an “outperform” rating and a $535.00 price target on the stock.
• 6/1/2026 – Thermo Fisher Scientific was upgraded by Wolfe Research to “strong-buy”.
• 5/26/2026 – Thermo Fisher Scientific had its “overweight” rating reaffirmed by KeyCorp.
• 5/14/2026 – Thermo Fisher Scientific was given a new $490.00 price target by Royal Bank Of Canada. They now have a “sector perform” rating on the stock.
• 5/14/2026 – Thermo Fisher Scientific was upgraded by Royal Bank Of Canada to “hold”.
• 5/9/2026 – Thermo Fisher Scientific was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/8/2026 – Thermo Fisher Scientific had its price target lowered by Wells Fargo & Company from $675.00 to $615.00. They now have an “overweight” rating on the stock.
• 4/27/2026 – Thermo Fisher Scientific had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $620.00 price target on the stock.
• 4/24/2026 – Thermo Fisher Scientific was upgraded by Jefferies Financial Group Inc. to “strong-buy”.
• 4/24/2026 – Thermo Fisher Scientific had its price target lowered by Stifel Nicolaus from $700.00 to $600.00. They now have a “buy” rating on the stock.
• 4/24/2026 – Thermo Fisher Scientific had its price target lowered by Robert W. Baird from $653.00 to $639.00. They now have an “outperform” rating on the stock.
• 4/14/2026 – Thermo Fisher Scientific had its price target lowered by Barclays PLC from $650.00 to $625.00. They now have an “overweight” rating on the stock.
• 4/8/2026 – Thermo Fisher Scientific had its “hold (c)” rating reaffirmed by Weiss Ratings.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.